All In Biotech

Investigational drug · Phase 2

CD38

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed or Refractory Multiple Myeloma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

245

Any phase or sponsor naming "CD38"

First trial start

2025

Jul 2, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CD38", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Relapsed or Refractory Multiple Myeloma

Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "CD38" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 11,449 on PubMed

Also in development for Relapsed or Refractory Multiple Myeloma

  • EtentamigABBV-383, TNB-383BPhase 38 trials

    AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis

  • BMS-986348CC-92480, mezigdomidePhase 37 trials

    Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma

  • IBI3003Phase 34 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma

  • QLS32015Phase 32 trials

    Qilu Pharmaceutical Co., Ltd. · Relapsed or Refractory Multiple Myeloma

  • QLS4131Phase 32 trials

    Qilu Pharmaceutical Co., Ltd. · Malignant Plasma Cell Neoplasms, Relapsed or Refractory Multiple Myeloma

  • MBS314Phase 22 trials

    Beijing Mabworks Biotech Co., Ltd. · Relapsed or Refractory Multiple Myeloma, Multiple Myeloma

  • AZD4045Phase 21 trial

    AstraZeneca · Relapsed or Refractory Multiple Myeloma

  • F182112Phase 21 trial

    Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.